Tag: HR

Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

TOPLINE: Belantamab mafodotin plus a combination of bortezomib and dexamethasone improved median progression-free survival (PFS) by 23 months in patients with relapsed or refractory multiple myeloma compared with daratumumab alongside the same combination. METHODOLOGY: Belantamab mafodotin, a first-in-class anti-BCMA monoclonal antibody conjugate, was approved in the US in 2020 for…

Continue Reading Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

OSAKA, Japan–(BUSINESS WIRE)– Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled Phase 2/3 study (SCORPIO-SR) in patients with mild to moderate COVID-19 in Japan, South Korea…

Continue Reading Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

rPFS and cPFS May Act as Surrogate OS End Points in Phase 3 mHSPC Clinical Trials

Both radiographic progression-free survival (rPFS) and clinical PFS (cPFS) appear to be valid surrogates for overall survival (OS) in phase 3 clinical trials evaluating testosterone suppression–based treatment strategies for patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to findings from a study that were published in the Journal of Clinical…

Continue Reading rPFS and cPFS May Act as Surrogate OS End Points in Phase 3 mHSPC Clinical Trials

Insight Global hiring Bioinformatics Software Engineer in Tennessee, United States

Job Description: 1) Use Nextflow to build bioinformatics pipelines that take FASTQ or BAM files as input and process them using bioinformatic tools. 2) Write Python/R scripts to process, summarize, and visualize outputs created by other tools. 3) Ensure that the pipeline is modular and flexible, with the ability to…

Continue Reading Insight Global hiring Bioinformatics Software Engineer in Tennessee, United States

Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC

Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC Compared with lenvatinib (Lenvima) plus placebo, adding pembrolizumab (Keytruda) to lenvatinib resulted in consistent overall (OS) and progression-free survival (PFS) outcomes previously found in the phase 3 LEAP-002 trial (NCT03713593) of patients with advanced hepatocellular carcinoma (HCC). However, 35% of…

Continue Reading Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC

FDA Approves Erdafitinib for FGFR3+ Locally Advanced or Metastatic Urothelial Carcinoma

The FDA has approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations, as determined by an FDA-approved test, whose disease has progressed on or following at least 1 prior line of systemic therapy. The agent is not recommended for those who are…

Continue Reading FDA Approves Erdafitinib for FGFR3+ Locally Advanced or Metastatic Urothelial Carcinoma

FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma With FGFR3 Mutations

FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma With FGFR3 Mutations The FDA has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic mutations whose disease has progressed on or after previously receiving one line of systemic…

Continue Reading FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma With FGFR3 Mutations

FDA Approves Balversa for Locally Advanced, Metastatic Urothelial Carcinoma

Image credit: Matthieu | stock.adobe.com The FDA has approved Balversa (erdafitinib) for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic mutations whose disease progressed on or following one line of systemic therapy.1 The regulatory action amends the accelerated approval granted by the FDA in April 2019 for patients…

Continue Reading FDA Approves Balversa for Locally Advanced, Metastatic Urothelial Carcinoma

Scientists study key steps in the road to DNA repair breakthrough

DNA is the blueprint of life, but it is constantly under attack from various sources of damage. The DNA is constantly exposed to various sources of damage, such as UV rays, chemicals, or errors during replication. One of the most serious types of damage is a double-strand break, where both…

Continue Reading Scientists study key steps in the road to DNA repair breakthrough

Senior Bioinformatics Research Scientist – Appcast

We are seeking a talented, highly motivated Senior Bioinformatics Research Scientist to lead our bioinformatics pipeline and develop innovative solutions for analyzing and visualizing omics data related to innate immune signaling projects. The candidate will work both collaboratively and independently on projects within the Kanneganti lab in the Department of…

Continue Reading Senior Bioinformatics Research Scientist – Appcast

FDA grants full approval to erdafitinib for FGFR3-positive urothelial carcinoma

The FDA has granted a full approval to erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least 1 line of prior systemic therapy. It is not recommended for patients who,…

Continue Reading FDA grants full approval to erdafitinib for FGFR3-positive urothelial carcinoma

What is new in bladder cancer treatment? The latest breakthroughs

According to the World Health Organisation, 573,278 new cases of bladder cancer were diagnosed in 2020, making it the 10th most common type of cancer. Bladder cancer most commonly starts in the urothelial cells lining the inside of the bladder but can also develop in other areas like the kidneys…

Continue Reading What is new in bladder cancer treatment? The latest breakthroughs

HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

In a recent conversation with CancerNetwork®, Sara A. Hurvitz, MD, FACP, senior vice president and director of the Clinical Research Division at Fred Hutch Cancer Center and head of the Division of Hematology and Oncology at the University of Washington Department of Medicine, discussed new treatment options for patients with…

Continue Reading HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer

Domestic pigs are susceptible to experimental infection with non-human primate-derived Reston virus without the need for adaptation

Ethics and animal welfare statement All infectious work with RESTV, including sample inactivation, was performed in the Containment Level 4 laboratory (CL4) in accordance with the policies and protocols outlined by the Canadian Science Centre for Human and Animal Health Institutional Biosafety Committee. All animal work was performed in strict…

Continue Reading Domestic pigs are susceptible to experimental infection with non-human primate-derived Reston virus without the need for adaptation

AI/ML Engineer Job in LTIMindtree at Other Maharashtra,Pune -Job Description #13777457

AI/ML Engineer Job in LTIMindtree at Other Maharashtra,Pune -Job Description #13777457 – Shine.com Hi Job Details AL/ML Engineer Mandatory Skills- Design and implement AI/ML models and solutions using Google Cloud Platform technologies, including Vertex AI, TensorFlow, PyTorch and Cloud TPUs. Design and implement AI/ML models. Develop a deep understanding of…

Continue Reading AI/ML Engineer Job in LTIMindtree at Other Maharashtra,Pune -Job Description #13777457

Early prognosis prediction in acute myeloid and acute lymphoid Leukaemia patients by cell free DNA (cfDNA) Concentration Ratios

1Indian Council of Medical Research (ICMR), India 2Vardhman Mahavir Medical College & Safdarjung Hospital, India The final, formatted version of the article will be published soon. Notify me Receive an email when it is updated You just subscribed to receive the final…

Continue Reading Early prognosis prediction in acute myeloid and acute lymphoid Leukaemia patients by cell free DNA (cfDNA) Concentration Ratios

Mark your route – The Hindu

I completed my Bachelor’s in Economics in 2021 but haven’t done anything relevant to put on a resume: no jobs or internships. How can I cover this gap? I want to try for the UPSC but what if I don’t clear it? I am thinking of higher studies (preferably abroad…

Continue Reading Mark your route – The Hindu

Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer

It was reported that the safety profile of dostarlimab combined with chemotherapy plus maintenance dostarlimab and niraparib in the phase 3 RUBY trial (NCT03981796) was found to be primarily consistent with the known profiles of each drug. Treatment with dostarlimab-gxly (Jemperli) plus carboplatin/paclitaxel followed by maintenance dostarlimab and niraparib (Zejula)…

Continue Reading Dostarlimab/Niraparib Improves PFS Outcomes in Advanced Endometrial Cancer

Doctoral scholarship holder bioinformatics – Academic Positions

Let’s shape the future – University of Antwerp The University of Antwerp is a dynamic, forward-thinking, European university. We offer an innovative academic education to more than 20000 students, conduct pioneering scientific research and play an important service-providing role in society. We are one of the largest, most international and most innovative…

Continue Reading Doctoral scholarship holder bioinformatics – Academic Positions

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Postdoc in the field of Integrative Bioinformatics and Biostatistics job with MASARYK UNIVERSITY

Department: RECETOX – Faculty of Science Deadline: 15 Jan 2024 Start date: upon agreement Job type: full-time Job field Science and research Bursar of the Faculty of Science, Masaryk University announces an open competition for the position Postdoc in the field of Integrative Bioinformatics and Biostatistics Workplace: RECETOX, Faculty of Science, Masaryk University in…

Continue Reading Postdoc in the field of Integrative Bioinformatics and Biostatistics job with MASARYK UNIVERSITY

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Background ALPINE, a randomized, multinational phase 3 study (NCT03734016) in patients with R/R CLL/SLL, established the statistical and clinically meaningful superiority of zanubrutinib over ibrutinib on progression-free survival (PFS) and overall response rate (ORR) and confirmed the favorable safety/tolerability profile of zanubrutinib (Brown et al. NEJM; 2022). Now, with 3…

Continue Reading Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes | Antibodies

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes Details Category: Antibodies Published on Tuesday, 19 December 2023 09:37 Hits: 742 TROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for early-stage triple negative and HR…

Continue Reading Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes | Antibodies

LncRNA/circRNA-mRNA networks in CARAS | JIR

Introduction Combined allergic rhinitis and asthma syndrome (CARAS), a new terminology introduced by the World Allergy Organization (WAO) in 2004, is an allergic reaction that occurs in the respiratory tract, including upper respiratory tract allergy (allergic rhinitis, AR) and lower respiratory tract allergy (asthma, AS).1,2 The incidence of AS in…

Continue Reading LncRNA/circRNA-mRNA networks in CARAS | JIR

ASH 2023: Lymphoma Studies May Inform Practice

Studies presented at the ASH Annual Meeting 2023 provided new insights and updates that may inform the treatment of lymphomas. Results from the phase 3 SYMPATICO trial showed that adding venetoclax to ibrutinib can improve progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL).1 These results…

Continue Reading ASH 2023: Lymphoma Studies May Inform Practice

MongoDB leaks data, but does not tell how much

MongoDB is still investigating a security incident in which hackers penetrated customers’ business systems. Contact information and metadata were allegedly accessed. The number of involved customers stays unclear. During the weekend of Dec. 16 and 17, a security incident occurred at MongoDB. On Saturday, it was reported that several company…

Continue Reading MongoDB leaks data, but does not tell how much

A super-pangenome of the North American wild grape species | Genome Biology

Alston JM, Sambucci O. Grapes in the world economy. In: Cantu D, Walker MA, editors. The grape genome. Springer International Publishing; 2019. p. 1–24. Google Scholar  Rahemi A, Dodson Peterson JC, Lund KT. Grape rootstocks and related species. Cham: Springer International Publishing; 2022. Walker MA, Heinitz C, Riaz S, Uretsky…

Continue Reading A super-pangenome of the North American wild grape species | Genome Biology

Characterization of runs of Homozygosity revealed genomic inbreeding and patterns of selection in indigenous sahiwal cattle

Almeida OAC, Moreira GCM, Rezende FM et al (2019) Identification of selection signatures involved in performance traits in a paternal broiler line. BMC Genomics 20:1–20. doi.org/10.1186/s12864-019-5811-1 Article  Google Scholar  Alshawi A, Essa A, Al-Bayatti S, Hanotte O (2019) Genome Analysis Reveals Genetic Admixture and Signature of Selection for Productivity and…

Continue Reading Characterization of runs of Homozygosity revealed genomic inbreeding and patterns of selection in indigenous sahiwal cattle

Medical Coding Jobs- Bsc Biotechnology Biomedical Bioinformatics Biochemistry Freshers/Experie Job For 0-5 Year Exp In I Skills Solutions Chennai, Thanjavur – 23795457

Job Description Medical Coding Job for Freshers – (2017 to 2023) Passed Out Ct HR Gomathy – 8428080909 Job in Chennai, CBE, Trichy, Vellore, Salem Job Description: Position : Medical Coder Medical Coding is the process of converting Verbal Descriptions into numeric or alpha numeric by using ICD 10-CM, CPT…

Continue Reading Medical Coding Jobs- Bsc Biotechnology Biomedical Bioinformatics Biochemistry Freshers/Experie Job For 0-5 Year Exp In I Skills Solutions Chennai, Thanjavur – 23795457

Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone —…

Continue Reading Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Keytruda Plus Padcev Approved for Locally Advanced or Metastatic Urothelial Cancer

The Food and Drug Administration (FDA) approved Keytruda® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial cancer. Previously, the treatment was approved only for patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-containing chemotherapy. The approval was…

Continue Reading Keytruda Plus Padcev Approved for Locally Advanced or Metastatic Urothelial Cancer

Pembrolizumab/Chemo Receives European Approval in First-Line GI Cancers

The approval was based on data from both the phase 3 KEYNOTE-859 study (NCT03675737) and the phase 3 KEYNOTE-966 study (NCT04003636). The European Commission has granted approval to pembrolizumab (Keytruda) and chemotherapy in 2 gastrointestinal cancer indications, according to a press release from Merck.1 In particular, pembrolizumab is available in…

Continue Reading Pembrolizumab/Chemo Receives European Approval in First-Line GI Cancers

Stocks Gain; Oil Rises as Conflict Disrupts Red Sea Shipping

Communications Sector Gets a Boost from FAANG 37 minutes ago The communications sector was the best-performing corner of the market Monday, buoyed by big tech firms Meta (META), Netflix (NFLX), and Alphabet (GOOGL). Shares of each were about 3% high Monday afternoon, possibly buoyed by conviction the digital advertising market is…

Continue Reading Stocks Gain; Oil Rises as Conflict Disrupts Red Sea Shipping

Programmable Genomic Integration Company Raises Over $200 Million

Tome Biosciences – a programmable genomic integration company – recently announced it has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence of any size into any programmed genomic location. And the company has raised…

Continue Reading Programmable Genomic Integration Company Raises Over $200 Million

BMS Ends Phase 3 Trial of Nivolumab and Relatlimab in CRC

Colorectal Cancer: © peterschreiber.media – stock.adobe.com Bristol Myers Squibb is ending the phase 3 RELATIVITY-123 trial (NCT05328908) investigating nivolumab (Opdivo) and relatlimab (Opdualag) in patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer (CRC) with disease progression following 1, but no more than 4 lines of therapy, due to…

Continue Reading BMS Ends Phase 3 Trial of Nivolumab and Relatlimab in CRC

Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity

Study objectives and endpoints The main objective consisted in identifying predictive biomarkers of efficacy by exploring correlation between baseline potential biomarkers and radiological and metabolic responses to afatinib. Secondary objectives were to identify potential pharmacodynamic biomarkers, to evaluate the efficacy and safety of afatinib and to assess the metabolic and…

Continue Reading Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity

Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

Systemic therapy and surgery have become mainstays in the treatment of patients with endometrial cancer, although further research is necessary to delineate the optimal use of radiation and later-line immunotherapy in this patient population, according to Hope Cottrill, MD. The phase 3 NRG-GY018 trial (NCT03914612) evaluated the efficacy and safety…

Continue Reading Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

Lecturer / Assistant Professor in Anatomy, School of Nursing, Midwifery and Health Systems job with UNIVERSITY COLLEGE DUBLIN (UCD)

Applications are invited for a permanent post of a Lecturer/Assistant Professor in Anatomy School of Nursing, Midwifery and Health Systems The School University College Dublin is a research-intensive and globally-engaged university and is No. 1 in Ireland in the QS Graduate Employability rankings. The UCD School of Nursing, Midwifery and…

Continue Reading Lecturer / Assistant Professor in Anatomy, School of Nursing, Midwifery and Health Systems job with UNIVERSITY COLLEGE DUBLIN (UCD)

Bioinformatics Scientist – Job at Spectraforce Technologies in Cambridge, MA

Title: Bioinformatics Scientist Location: Cambridge, MA 02141 Duration: 12 Months Pay rate starts from $70/hr. Note: * Shift: M-F(9am-6pm)EST * Work location: Cambridge, MA-Hybrid (2 days/week) or Remote (ideally, eastern time zone) Qualifications: Education Minimum Requirement: * Ph.D. (or 5+ years of relevant experience) in Bioinformatics, Biostatistics, Computational…

Continue Reading Bioinformatics Scientist – Job at Spectraforce Technologies in Cambridge, MA

Data Science Hiring Process at Marlabs

Founded in 2011, New York-based IT services and consulting firm Marlabs helps companies of various sizes to undergo AI-powered digital transformation. It provides a wide range of services, including strategic planning, creating rapid prototypes in specialised labs, and applying agile engineering techniques to develop and expand digital solutions, cloud-based applications…

Continue Reading Data Science Hiring Process at Marlabs

Gadolinium Oxide Nanoparticles reinforce immune response

Boyi Yu,1– 4 Xuanyi Lu,5 Xianglong Feng,1– 4 Ting Zhao,1– 4 Jiaxin Li,1– 4 Yudie Lu,5 Fei Ye,1– 4 Xiongxiong Liu,1– 4 Xiaogang Zheng,1– 4 Zheyu Shen,5 Xiaodong Jin,1– 4 Weiqiang Chen,1– 4 Qiang Li1– 4 1Biomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, People’s Republic of…

Continue Reading Gadolinium Oxide Nanoparticles reinforce immune response

Fatty Acid Metabolism-Related lncRNAs as Biomarkers for SKCM

Introduction Skin cutaneous melanoma (SKCM), as one of the most aggressive types of cancer due to its elevated degree of heterogeneity, has gained increasing attention during the past few decades.1 Also known as “the cancer that rises with the sun”,2 melanoma originates from cancerous melanocytes due to molecular or genetic…

Continue Reading Fatty Acid Metabolism-Related lncRNAs as Biomarkers for SKCM

Enfortumab Vedotin Combo Is Approved by FDA for Advanced Urothelial Cancer

The News Enfortumab vedotin-ejfc (Padcev) plus pembrolizumab (Keytruda) has been approved by the FDA for patients with locally advanced or metastatic urothelial cancer, according to a press release from the organization. Enfortumab Vedotin’s Efficacy The median overall survival (OS) was 31.5 months (95% CI, 24.4-not estimable) in the combination arm…

Continue Reading Enfortumab Vedotin Combo Is Approved by FDA for Advanced Urothelial Cancer

Identification of Differentially Expressed Genes in Human Colorectal Cancer Using RNASeq Data Validated on the Molecular Level with Real-Time PCR

Allam RM, Al-Abd AM, Khedr A, Sharaf OA, Nofal SM, Khalifa AE, Mosli HA, Abdel-Naim AB (2018) Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett 291:77–85 Article  CAS  PubMed  Google Scholar  Andrews S et al (2010) FastQC: a quality control tool…

Continue Reading Identification of Differentially Expressed Genes in Human Colorectal Cancer Using RNASeq Data Validated on the Molecular Level with Real-Time PCR

Zanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)

Treatment with the BTK inhibitor zanubrutinib (Brukinsa) conferred a progression-free survival (PFS) benefit compared with bendamustine plus rituximab (Rituxan) across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without del(17p), according to findings from the phase 3 SEQUOIA trial (NCT03336333) presented as…

Continue Reading Zanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)

FDA Approves Belzutifan in Advanced RCC

Results from the phase 3 LITESPARK-005 trial led to the approval of belzutifan for patients with advanced renal cell carcinoma, according to the FDA. The FDA has approved belzutifan (Welireg) for patients with advanced renal cell carcinoma (RCC) after a PD-L1/PD-1 inhibitor and VEGF tyrosine kinase inhibitor (TKI) for patients…

Continue Reading FDA Approves Belzutifan in Advanced RCC

RP1 Plus Cemiplimab Misses Response End Points in Locally Advanced or Metastatic CSCC

Philip Astley-Sparke, chief executive officer of Replimune Group, Inc. The combination of RP1 and cemiplimab-rwlc (Libtayo) provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), missing the primary end points of the phase…

Continue Reading RP1 Plus Cemiplimab Misses Response End Points in Locally Advanced or Metastatic CSCC

FDA Approves Belzutifan for Adult Patients With Advanced RCC

This approval of belzutifan (Welireg) for the treatment of advanced renal cell carcinoma (RCC) is supported by findings from the phase 3 LITESPARK-005 study (NCT04195750). Statistically significant and clinically meaningful improvements in progression-free survival (PFS) were observed with belzutifan. This approval provides adult patients with RCC who progressed on immune…

Continue Reading FDA Approves Belzutifan for Adult Patients With Advanced RCC

Subcutaneous Daratumumab is Safe and Tolerable in Multiple Myeloma

Bone marrow aspirate cytology of multiple myeloma: ©David A Litman – stock.adobe.com Findings from the phase 3 PERSEUS study (NCT03710603) presented at the 2023 ASH Annual Meeting showed that subcutaneous daratumumab (Darzalex) followed by autologous stem cell transplant (ASCT) and daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation and…

Continue Reading Subcutaneous Daratumumab is Safe and Tolerable in Multiple Myeloma

Clinical Challenges: CAR-T or Bispecifics in Relapsed/Refractory DLBCL

T-cell engaging therapeutic approaches have significantly changed the treatment paradigm for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in recent years. “They are, by a wide margin, the most impactful new therapies for all B-cell lymphomas, but especially DLBCL, in the last 40 years, if not ever,” said Joshua…

Continue Reading Clinical Challenges: CAR-T or Bispecifics in Relapsed/Refractory DLBCL

Molecular Techniques | SpringerLink

Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR et al (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53–59 CrossRef  CAS  PubMed  PubMed Central  Google Scholar  Büyükköroğlu G, Dora DD, Özdemir F, Hızel C (2018)…

Continue Reading Molecular Techniques | SpringerLink

Complete Interim Response, SCT Beats CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Complete Interim Response, SCT Beats CAR T

Measurable Residual Disease-Guided Therapy Promising in CLL

SAN DIEGO — In untreated chronic lymphocytic leukemia (CLL), patients who received ibrutinib plus venetoclax for a duration determined by disease characteristics rather than a fixed schedule had significantly better progression-free and overall survival compared with conventional chemoimmunotherapy, a new phase 3 analysis shows. The targeted therapy combination was also…

Continue Reading Measurable Residual Disease-Guided Therapy Promising in CLL

Retrieval Augmented Generation using Vertex AI Search + Langchain + Gradio | by Parag Mhatre | Dec, 2023

Retrieval argument generation is a NLP technique where AI models generate arguments by leveraging relevant information from external sources. It combines the strengths of two approaches: 1. Retrieval: This involves searching and identifying existing documents or passages rich in information supporting the desired argument. The system then analyzes these retrieved…

Continue Reading Retrieval Augmented Generation using Vertex AI Search + Langchain + Gradio | by Parag Mhatre | Dec, 2023

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform Technology, in-licensed from the Massachusetts Institute of Technology (MIT), capable of inserting DNA sequences of any size into any programmed genomic location Potential to create curative cell and integrative gene therapies Backed by leading biotech…

Continue Reading Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Human RAD52 stimulates the RAD51-mediated homology search

Introduction Homologous recombination (HR) is an evolutionarily conserved process that plays a pivotal role in genome stability, diversity, and plasticity. HR is indeed a key repair pathway able to faithfully repair DNA damages including double-strand breaks (DSBs) and DNA gaps by copying the error-free information from the template DNA normally…

Continue Reading Human RAD52 stimulates the RAD51-mediated homology search

Transition of allele-specific DNA hydroxymethylation at regulatory loci is associated with phenotypic variation in monozygotic twins discordant for psychiatric disorders | BMC Medicine

Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373(9659):234–9. Article  PubMed  Google Scholar  Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R,…

Continue Reading Transition of allele-specific DNA hydroxymethylation at regulatory loci is associated with phenotypic variation in monozygotic twins discordant for psychiatric disorders | BMC Medicine

Trem-cel a CRISPR/Cas9-Edited Allograft Devoid of CD33 Shows Rapid Engraftment in High-Risk Acute Myeloid Leukemia

Trem-cel, a CRISPR/Cas9 gene-edited allograft, demonstrated rapid primary engraftment among patients with high-risk acute myeloid leukemia (AML), according to results of a study that were presented at the ASH Annual Meeting 2023. Trem-cel (VOR33) uses CRISPR/Cas9 technology to delete CD33 in allograft tissue. It was developed to protect normal hematopoietic…

Continue Reading Trem-cel a CRISPR/Cas9-Edited Allograft Devoid of CD33 Shows Rapid Engraftment in High-Risk Acute Myeloid Leukemia

Racial, ethnic disparities in mortality risk shown among younger patients with DLBCL

December 11, 2023 3 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . ” data-action=subscribe> Subscribe We were unable to process your request. Please try again later….

Continue Reading Racial, ethnic disparities in mortality risk shown among younger patients with DLBCL

Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

Zanubrutinib Showcases Sustained PFS Benefit Vs Ibrutinib in R/R CLL/SLL

Jennifer R. Brown, MD, PhD Zanubrutinib (Brukinsa) continued to demonstrate improved progression-free survival (PFS) benefit over ibrutinib (Imbruvica) in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to extended follow-up data from the phase 3 ALPINE trial (NCT03734016) presented at the 2023…

Continue Reading Zanubrutinib Showcases Sustained PFS Benefit Vs Ibrutinib in R/R CLL/SLL

Bristol-Myers Squibb (BMY) Reports Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl

Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS) (Oral Presentation #193) who may require red blood cell (RBC)…

Continue Reading Bristol-Myers Squibb (BMY) Reports Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl

New Data Presented at ASH from the Phase 3 GLOW Study Show

Additional data from the Phase 2 CAPTIVATE study, show 82 percent of patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with fixed-duration ibrutinib plus venetoclax did not need next-line treatment at 54 months1,2 BEERSE, BELGIUM, Dec. 11, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of Johnson & Johnson…

Continue Reading New Data Presented at ASH from the Phase 3 GLOW Study Show

Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL

Treatment with odronextamab (REGN1979) led to an objective response rate (ORR) of 52%, with encouraging progression-free (PFS) and overall survival (OS) among complete responders in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a final analysis of the phase 2 ELM-2 trial (NCT03888105) presented at…

Continue Reading Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL

Updated Odronextamab Data from Relapsed/Refractory Diffuse

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the…

Continue Reading Updated Odronextamab Data from Relapsed/Refractory Diffuse

Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “Bladder Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline…

Continue Reading Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

No Significant Differences at 5 Year Follow-Up Between Palbociclib-Based Treatment Regimens

Results from the PARSIFAL-LONG study investigating endocrine-sensitive hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer demonstrated the efficacy of 2 combined option therapies, palbociclib (Ibrance; Pfizer) plus letrozole (Femara; Novartis) and palbociclib plus fulvestrant (Faslodex; Hikma), as first-line treatments for metastatic breast cancer. The study found no significant differences in progression-free survival…

Continue Reading No Significant Differences at 5 Year Follow-Up Between Palbociclib-Based Treatment Regimens

Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility

The phase 3 KEYLYNK-008 trial (NCT03976362) evaluating pembrolizumab (Keytruda) plus olaparib (Lynparza) in patients with metastatic squamous non–small cell lung cancer (NSCLC) will be discontinued for futility, according to an announcement from Merck.1 The decision was based on a recommendation issued by an independent data monitoring committee (IDMC) after reviewing…

Continue Reading Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility

Analyses Probe into Co-Mutation Activity of Sotorasib in KRAS-Mutant NSCLC

Devika Das, MD Associate Professor UAB Medicine Birmingham, AL LINK TO PART 1 Targeted Oncology: What data support the use of sotorasib (Lumakras) in patients with non–small cell lung cancer (NSCLC) and a KRAS G12C mutation? DEVIKA DAS, MD: The CodeBreaK 100 study [NCT03600883] was a registrational phase 2 study….

Continue Reading Analyses Probe into Co-Mutation Activity of Sotorasib in KRAS-Mutant NSCLC

Bioinformatics Intern job with Element Biosciences

At Element Biosciences, we are passionate about our mission to empower the scientific community with more freedom and flexibility to accelerate our collective impact on humanity. We have built a highly efficient product-driven organization where employees can learn, grow, and thrive in a challenging but encouraging environment. We are committed…

Continue Reading Bioinformatics Intern job with Element Biosciences

r – How to make a forest plot with a table for CI and ORs with ggplot?

I am creating a forest plot adapting a script I found online. However, my variable labels and data do not fit the space given to the plot on the left after joining the plot in the middle. The current script gives the following plot: Current plot library(tidyverse) library(gt) setwd (“C:/~Forest…

Continue Reading r – How to make a forest plot with a table for CI and ORs with ggplot?

FDA grants IND clearance to DARE-VVA1 for dyspareunia

FDA grants IND clearance to DARE-VVA1 for dyspareunia | Image Credit: © Postmodern Studio – © Postmodern Studio – stock.adobe.com. The FDA has cleared an investigational new drug (IND) application for DARE-VVA1, according to Daré Bioscience, Inc.1 Takeaways The FDA has granted clearance for an Investigational New Drug (IND) application…

Continue Reading FDA grants IND clearance to DARE-VVA1 for dyspareunia

Senior Bioinformatics Scientist – 127022

UCSD Layoff from Career Appointment: Apply by 12/08/2023 for consideration with preference for rehire. All layoff applicants should contact their Employment Advisor. Special Selection Applicants: Apply by 12/20/2023. Eligible Special Selection clients should contact their Disability Counselor for assistance. This position will work a hybrid schedule which includes a combination…

Continue Reading Senior Bioinformatics Scientist – 127022

r – ggplot2 shapes superimposed even when specified directly

I’m trying to make a simple graph where one variable is shape and the other is fill in ggplot2. I’ve tried grouping the samples by different variables, and I’ve tried manually specifying the shapes for each variable, but every time I get this superimposed image where each sample has many…

Continue Reading r – ggplot2 shapes superimposed even when specified directly

Advancements in Non-human Forensic DNA Analysis

Alahi MEE, Mukhopadhyay SC (2017) Detection methodologies for pathogen and toxins: a review. Sensors 1885:17 Google Scholar  Aly SM, Sabri DM (2015) Next generation sequencing (NGS): a golden tool in forensic toolkit. Archiwum Medycyny Sądowej i Kryminologii/Archives of Forensic Medicine and Criminology 65(4):260–271 Google Scholar  Amendt J, Richards CS, Campobasso…

Continue Reading Advancements in Non-human Forensic DNA Analysis

Advanced Emerging Techniques for Forensic DNA Analysis: STRs, SNPs, and mtDNA Analysis

Alshehhi A, Almarzooqi A, Alhammadi K, Werghi N, Tay GK, Alsafar H (2023) Advancement in human face prediction using DNA. Genes (Basel) 14:136. doi.org/10.3390/genes14010136 CrossRef  CAS  PubMed  Google Scholar  Amorim A, Fernandes T, Taveira N (2019) Mitochondrial DNA in human identification: a review. PeerJ 7:e7314. doi.org/10.7717/peerj.7314 CrossRef  PubMed Central  PubMed …

Continue Reading Advanced Emerging Techniques for Forensic DNA Analysis: STRs, SNPs, and mtDNA Analysis

Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer

Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer An analysis of patient-reported outcomes (PROs) from the phase 3 CAPItello-291 trial (NCT04305496) showed positive health-related quality-of-life (HRQOL) outcomes with capivasertib (Truqap) plus fulvestrant (Faslodex) among those with aromatase inhibitor (AI)-resistant hormone receptor-positive/HER2-negative advanced breast cancer. Findings…

Continue Reading Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer

Circular RNA Associated With Higher Risk and Poor Outcomes in MDS and AML

The circular RNA (circRNA) circZBTB46 was expressed at increasing levels among patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and was associated with shorter survival, according to the results of a study published in the journal Clinical and Experimental Medicine. A type of noncoding, stable RNA,…

Continue Reading Circular RNA Associated With Higher Risk and Poor Outcomes in MDS and AML

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma, Business News

modeling – Trouble solving the system of nonlinear differential equations in sage math

I am solving a 9×9 system of ordinary differential equations. In simple terms, I need to get the equilibrium expressions for the system. I am using the solve command in sage, but I get an error whose cause I don’t know. Kindly help. Declare variables “mu_h,beta,alpha,gamma_r,gamma_s,omega,mu_m,epsilon,theta,N_h,S_h,I_hr,I_hs,I_hsr,R_h,N_m,S_m,I_mr,I_ms,I_msr = var(‘mu_h,beta,alpha,gamma_r,gamma_s,omega,mu_m,epsilon,theta,N_h,S_h,I_hr,I_hs,I_hsr,R_h,N_m,S_m,I_mr,I_ms,I_msr’) System of…

Continue Reading modeling – Trouble solving the system of nonlinear differential equations in sage math

Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating…

Continue Reading Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma USA – English APAC – Traditional Chinese APAC – English

FDA to Review Confirmatory Data for Elahere in Platinum-Resistant Ovarian Cancer

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) supporting the conversion to full approval of Elahere (mirvetuximab soravtansine-gynx) in the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have…

Continue Reading FDA to Review Confirmatory Data for Elahere in Platinum-Resistant Ovarian Cancer

Roche’s bid to build a better Piqray yields phase 3 breast cancer win, opening door to regulators

Roche’s pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle. The drugmaker’s attempt to improve on Novartis’ Piqray and deliver a first-line PI3K inhibitor has yielded an improved progression-free survival (PFS) in phase 3, teeing up talks with regulatory authorities.  The investigational…

Continue Reading Roche’s bid to build a better Piqray yields phase 3 breast cancer win, opening door to regulators

Frontline Nivolumab/Chemo Earns FDA Priority Review in Urothelial Carcinoma

Supporting data for the application came from the phase 3 CheckMate 901 trial (NCT03036098), which investigators presented at the 2023 European Society for Medical Oncology Congress (ESMO)and subsequently published in The New England Journal of Medicine. The FDA has granted priority review to a supplemental biologics license application for frontline…

Continue Reading Frontline Nivolumab/Chemo Earns FDA Priority Review in Urothelial Carcinoma

Identification and validation of key miRNAs for colon cancer

Introduction With nearly 2 million new cases and 1 million deaths worldwide in 2020, colorectal cancer is the third-most common cancer and the second leading cause of cancer-related deaths.1 According to data from the US Surveillance, Epidemiology and End Results program and the National Program of Cancer Registries program, the…

Continue Reading Identification and validation of key miRNAs for colon cancer

Microbial gene expression analysis of healthy and cancerous esophagus uncovers bacterial biomarkers of clinical outcomes

Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding esophageal cancer: the challenges and opportunities for the next decade. Front Oncol. 2020;10:1727. Article  PubMed  PubMed Central  Google Scholar  Li J, Xu J, Zheng Y, Gao Y, He S, Li H, et al. Esophageal cancer: epidemiology, risk…

Continue Reading Microbial gene expression analysis of healthy and cancerous esophagus uncovers bacterial biomarkers of clinical outcomes

NOTCH1 mutations predict superior outcomes, NSCLC

Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, and the majority are non-small-cell lung cancer (NSCLC).1,2 Genetic variation is a typical feature of NSCLC that drives cancer initiation and progression.3 Understanding the role of mutated genes in NSCLC is the basis of the development of novel treatment…

Continue Reading NOTCH1 mutations predict superior outcomes, NSCLC

Next-Generation Sequencing of Microbial Cell-Free DNA to Rapidly Detect Fluoribacter Bozemanae Pneumonia in an Immunocompromised Host

Raihaan Khattak1, Rameez Rao2, Gurjot Garcha3, Mario Madruga1, Antonio Crespo1, SJ Carlan4* 1Division of Infectious Disease, USA2Department of Internal Medicine, USA3Division of Pulmonary and Critical Care Medicine, USA4Division of Academic Affairs and Research, Orlando Regional Medical Center, Orlando, Florida, USA *Correspondence author: SJ Carlan, Division of Academic Affairs and Research,…

Continue Reading Next-Generation Sequencing of Microbial Cell-Free DNA to Rapidly Detect Fluoribacter Bozemanae Pneumonia in an Immunocompromised Host

MSIX dependency – Microsoft Community Hub

Hi, I created an MSIX package with Advanced Installer named R for Windows. Package runs great, with no problems. I have another package R Studio what depends on R for Windows, so without R for Windows R Studio doesn’t start.  So  i added an dependency in the R Studio MSIX…

Continue Reading MSIX dependency – Microsoft Community Hub

FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer

Supporting data for the sBLA came from the phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856), in which the pembrolizumab combination significantly extended the primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with locally advanced or metastatic urothelial cancercompared withstandard platinum-containing chemotherapy. The FDA has given priority review to…

Continue Reading FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer

Pembrolizumab Plus Enfortumab Vedotin Under Review for First-Line Tx of Urothelial Cancer

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab in combination with enfortumab vedotin-ejfv for the first-line treatment of patients with locally advanced or metastatic urothelial cancer. The sBLA is supported by data from the phase 3 KEYNOTE-A39 trial (ClinicalTrials.gov

Continue Reading Pembrolizumab Plus Enfortumab Vedotin Under Review for First-Line Tx of Urothelial Cancer

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

Abstract A major unmet need in the cystic fibrosis (CF) therapeutic landscape is the lack of effective treatments for nonsense CFTR mutations, which affect approximately 10% of CF patients. Correction of nonsense CFTR mutations via genomic editing represents a promising therapeutic approach. In this study, we tested whether prime editing,…

Continue Reading Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

Ryvu Therapeutics Reports Third Quarter 2023 Financial

The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022. Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of Hematology (ASH) Annual Meeting in December. Preparations for executing Phase II clinical trials of RVU120 in…

Continue Reading Ryvu Therapeutics Reports Third Quarter 2023 Financial

Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Lung Cancer at the 2023 Multidisciplinary Thoracic Cancers Symposium

Individuals with higher quantities of cancer signal from cell-free DNA (cfDNA) prior to treatment had a significantly increased likelihood of recurrence post-treatment Adela’s tissue-agnostic platform shows potential to inform treatment decisions by predicting prognosis FOSTER CITY, Calif., Nov. 30, 2023 /PRNewswire/ — Adela, Inc., an innovator in blood testing for minimal…

Continue Reading Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Lung Cancer at the 2023 Multidisciplinary Thoracic Cancers Symposium

Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease | Cellular & Molecular Biology Letters

Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012;2(5): a006148. Article  PubMed  PubMed Central  Google Scholar  van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005;76(suppl 5):v2-7. Article  PubMed  PubMed Central …

Continue Reading Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease | Cellular & Molecular Biology Letters

Bioinformatics Programmer 2 – 126859

This is a 100% Contract position for one year. This appointment may be extended or converted to career status based on the needs of the department. UC San Diego is a student-centered, research-focused, service-oriented public institution, recognized as one of the top 15 research universities worldwide. The University fosters a…

Continue Reading Bioinformatics Programmer 2 – 126859

Senior Data Scientist (Biostatistics and Bioinformatics Core (BBC)

Senior Data Scientist (Biostatistics and Bioinformatics Core (BBC) University Overview The University of Pennsylvania, the largest private employer in Philadelphia, is a world-renowned leader in education, research, and innovation. This historic, Ivy League school consistently ranks among the top 10 universities in the annual U.S. News & World Report survey….

Continue Reading Senior Data Scientist (Biostatistics and Bioinformatics Core (BBC)

Entry Bioinformatics Professional Cancer Research job with University of Colorado Anschutz Medical Campus

Entry Bioinformatics Professional – Cancer Research – 31970 University Staff Description University of Colorado Anschutz Medical Campus Department: Pediatrics – Hematology, Oncology, and Bone Marrow Transplant Job Title: Entry Bioinformatics Professional – Cancer Research Position: # 00817933 – Requisition: # 31970 Job Summary: The Entry Bioinformatics Professional utilizes applied or…

Continue Reading Entry Bioinformatics Professional Cancer Research job with University of Colorado Anschutz Medical Campus